• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Use of low doses of bromocriptine in chronic schizophrenia resistant to neuroleptics. A preliminary study].[低剂量溴隐亭用于对抗精神病药物耐药的慢性精神分裂症。一项初步研究]
J Psychiatry Neurosci. 1992 Jun;17(2):68-71.
2
[Comparative efficacy of bromocriptine, carbamazepine and cyproheptadine with neuroleptics in 24 refractory chronic schizophrenic patients].[溴隐亭、卡马西平和赛庚啶与抗精神病药物对24例难治性慢性精神分裂症患者的疗效比较]
Encephale. 1993 Sep-Oct;19(5):565-71.
3
[Schizophrenia and violence, incidence and risk factors: a Tunisian sample].[精神分裂症与暴力：发病率及风险因素：突尼斯样本]
Encephale. 2009 Sep;35(4):347-52. doi: 10.1016/j.encep.2008.04.006. Epub 2008 Sep 20.
4
[The use of the bromocriptine test in schizophrenia patients resistant to neuroleptic therapy].[溴隐亭试验在对抗精神病药物治疗耐药的精神分裂症患者中的应用]
Zh Nevropatol Psikhiatr Im S S Korsakova. 1992;92(3):79-80.
5
[Complete neuroleptic withdrawal in patients with schizophrenia with intense symptoms and resistant to treatment].[症状严重且治疗抵抗的精神分裂症患者完全停用抗精神病药物]
Encephale. 1991 Jul-Aug;17(4):255-61.
6
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.一项加拿大多中心安慰剂对照研究，比较固定剂量的利培酮和氟哌啶醇治疗慢性精神分裂症患者的疗效。
J Clin Psychopharmacol. 1993 Feb;13(1):25-40.
7
Low-dose bromocriptine in neuroleptic-resistant schizophrenia: a pilot study.低剂量溴隐亭治疗难治性精神分裂症的初步研究。
Biol Psychiatry. 1992 Jun 1;31(11):1166-8. doi: 10.1016/0006-3223(92)90163-t.
8
The behavioral toxicity of bromocriptine in patients with psychiatric illness.溴隐亭对精神疾病患者的行为毒性。
J Clin Psychopharmacol. 1989 Dec;9(6):417-22.
9
A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.一项针对病情复发的依从药物治疗的精神分裂症患者的药物治疗研究。
J Clin Psychiatry. 1994 Nov;55(11):470-2.
10
Low-dose bromocriptine in the early phases of Parkinson's disease.低剂量溴隐亭用于帕金森病早期阶段
Clin Neuropharmacol. 1987 Apr;10(2):168-74.

本文引用的文献

1
Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy.小剂量溴隐亭治疗精神病的效果：多巴胺自身受体刺激策略
Psychopharmacology (Berl). 1983;81(1):37-41. doi: 10.1007/BF00439271.
2
Dopamine autoreceptor stimulation: clinical significance.
Pharmacol Biochem Behav. 1982;17 Suppl 1:1-10. doi: 10.1016/0091-3057(82)90504-4.
3
Low dose bromocriptine: a study of acute effects in chronic mediated schizophrenics.低剂量溴隐亭：对慢性介导型精神分裂症患者的急性效应研究
Prog Neuropsychopharmacol Biol Psychiatry. 1984;8(2):277-83. doi: 10.1016/0278-5846(84)90165-9.
4
An un-dopamine hypothesis of schizophrenia.
Schizophr Bull. 1980;6(3):387-9. doi: 10.1093/schbul/6.3.387.
5
Bromocriptine in the treatment of neuroleptic-resistant schizophrenia.溴隐亭治疗抗精神病药物耐药的精神分裂症
Biol Psychiatry. 1986 May;21(5-6):519-21. doi: 10.1016/0006-3223(86)90193-9.
6
Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics.低剂量溴隐亭对使用氟哌啶醇治疗的精神分裂症患者的急性和亚慢性影响。
Biol Psychiatry. 1989 Feb 1;25(3):247-55. doi: 10.1016/0006-3223(89)90172-8.
7
[Dopanergic agonists and schizophrenia].[多巴胺能激动剂与精神分裂症]
Psychiatr J Univ Ott. 1989 Nov;14(4):529-35.
8
Psychiatric applications of bromocriptine therapy.溴隐亭疗法的精神科应用。
J Clin Psychiatry. 1990 Feb;51(2):68-82.
9
Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists.多巴胺自身受体和突触后受体：对多巴胺激动剂敏感性差异的电生理学证据
Science. 1979 Oct 5;206(4414):80-2. doi: 10.1126/science.482929.
10
The role of presynaptic receptors in the release and synthesis of 3H-dopamine by slices of rat striatum.突触前受体在大鼠纹状体切片释放和合成3H-多巴胺中的作用。
Naunyn Schmiedebergs Arch Pharmacol. 1976;292(3):279-87. doi: 10.1007/BF00517390.

[低剂量溴隐亭用于对抗精神病药物耐药的慢性精神分裂症。一项初步研究]

[Use of low doses of bromocriptine in chronic schizophrenia resistant to neuroleptics. A preliminary study].

作者信息

Wolf M A, Diener J M, Lajeunesse C, Shriqui C

机构信息

Centre hospitalier Douglas, Centre de psychiatrie communautaire, Verdun, Québec, Canada.

出版信息

J Psychiatry Neurosci. 1992 Jun;17(2):68-71.

PMID:1637801
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1188403/
Abstract

In this work, we report the efficiency of bromocriptine (1.25 and 2.5 mg/day) in 9 neuroleptic resistant chronic schizophrenics. Following an initial four-week placebo period, the subjects successively received bromocriptine (1.25 mg/day), placebo and bromocriptine (2.5 mg/day). The 2 bromocriptine treatments significantly improved the global psychiatric symptomatology and different scores and factors related to the more specific schizophrenic symptomatology. An escape phenomenon seems to occur during the 4th week of the first bromocriptine treatment (1.25 mg/day) but is not observed with the second treatment (2.5 mg/day). All patients improved.

摘要

在本研究中，我们报告了溴隐亭（每日1.25毫克和2.5毫克）对9例耐抗精神病药物的慢性精神分裂症患者的疗效。在最初为期四周的安慰剂期之后，受试者依次接受溴隐亭（每日1.25毫克）、安慰剂以及溴隐亭（每日2.5毫克）治疗。两次溴隐亭治疗均显著改善了整体精神症状以及与更具体的精神分裂症症状相关的不同评分和因素。在首次溴隐亭治疗（每日1.25毫克）的第4周似乎出现了一种撤药现象，但在第二次治疗（每日2.5毫克）中未观察到。所有患者均有改善。